1. Home
  2. AGIO vs NEXT Comparison

AGIO vs NEXT Comparison

Compare AGIO & NEXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGIO
  • NEXT
  • Stock Information
  • Founded
  • AGIO 2007
  • NEXT 2010
  • Country
  • AGIO United States
  • NEXT United States
  • Employees
  • AGIO N/A
  • NEXT N/A
  • Industry
  • AGIO Biotechnology: Pharmaceutical Preparations
  • NEXT Oil & Gas Production
  • Sector
  • AGIO Health Care
  • NEXT Energy
  • Exchange
  • AGIO Nasdaq
  • NEXT Nasdaq
  • Market Cap
  • AGIO 2.0B
  • NEXT 1.9B
  • IPO Year
  • AGIO 2013
  • NEXT N/A
  • Fundamental
  • Price
  • AGIO $30.28
  • NEXT $8.05
  • Analyst Decision
  • AGIO Buy
  • NEXT Hold
  • Analyst Count
  • AGIO 8
  • NEXT 1
  • Target Price
  • AGIO $56.57
  • NEXT $9.00
  • AVG Volume (30 Days)
  • AGIO 637.9K
  • NEXT 1.8M
  • Earning Date
  • AGIO 05-01-2025
  • NEXT 05-08-2025
  • Dividend Yield
  • AGIO N/A
  • NEXT N/A
  • EPS Growth
  • AGIO N/A
  • NEXT N/A
  • EPS
  • AGIO 11.64
  • NEXT N/A
  • Revenue
  • AGIO $36,498,000.00
  • NEXT N/A
  • Revenue This Year
  • AGIO $50.61
  • NEXT N/A
  • Revenue Next Year
  • AGIO $223.79
  • NEXT N/A
  • P/E Ratio
  • AGIO $2.60
  • NEXT N/A
  • Revenue Growth
  • AGIO 36.07
  • NEXT N/A
  • 52 Week Low
  • AGIO $27.14
  • NEXT $4.27
  • 52 Week High
  • AGIO $62.58
  • NEXT $9.71
  • Technical
  • Relative Strength Index (RSI)
  • AGIO 39.54
  • NEXT 49.10
  • Support Level
  • AGIO $30.00
  • NEXT $8.50
  • Resistance Level
  • AGIO $32.90
  • NEXT $9.71
  • Average True Range (ATR)
  • AGIO 1.22
  • NEXT 0.52
  • MACD
  • AGIO -0.08
  • NEXT 0.08
  • Stochastic Oscillator
  • AGIO 9.12
  • NEXT 46.29

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About NEXT NextDecade Corporation

NextDecade Corp is a Houston-based energy company engaged in construction and development activities related to the liquefaction of natural gas and sale of LNG and the capture and storage of CO2 emissions. The group is constructing and developing a natural gas liquefaction and export facility located in the Rio Grande Valley near Brownsville, Texas (the Rio Grande LNG Facility). It also engaged in NEXT Carbon Solutions advancing proprietary processes to lower the cost of utilizing carbon capture and storage (CCS) and help companies reduce their emissions and achieve their clean energy goals.

Share on Social Networks: